Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Equity Income: 2018-2024

Historic Equity Income for BridgeBio Pharma (BBIO) over the last 3 years, with Dec 2024 value amounting to -$31.2 million.

  • BridgeBio Pharma's Equity Income fell 141.26% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$68.3 million, marking a year-over-year decrease of 164.61%. This contributed to the annual value of -$31.2 million for FY2024, which is N/A change from last year.
  • BridgeBio Pharma's Equity Income amounted to -$31.2 million in FY2024, which was down 49.42% from -$20.9 million recorded in FY2019.
  • In the past 5 years, BridgeBio Pharma's Equity Income registered a high of -$31.2 million during FY2024, and its lowest value of -$31.2 million during FY2024.
  • Moreover, its 1-year median value for Equity Income was -$31.2 million (2024), whereas its average is -$31.2 million.